Pro- and Anti-Inflammatory Prostaglandins and Cytokines in Humans: A Mini Review
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Inflammation has been described for two millennia, but cellular aspects and the paradigm involving different mediators have been identified in the recent century. Two main groups of molecules, the prostaglandins (PG) and the cytokines, have been discovered and play a major role in inflammatory processes. The activation of prostaglandins PGE2, PGD2 and PGI2 results in prominent symptoms during cardiovascular and rheumatoid diseases. The balance between pro- and anti-inflammatory compounds is nowadays a challenge for more targeted therapeutic approaches. The first cytokine was described more than a century ago and is now a part of different families of cytokines (38 interleukins), including the IL-1 and IL-6 families and TNF and TGFβ families. Cytokines can perform a dual role, being growth promotors or inhibitors and having pro- and anti-inflammatory properties. The complex interactions between cytokines, vascular cells and immune cells are responsible for dramatic conditions and lead to the concept of cytokine storm observed during sepsis, multi-organ failure and, recently, in some cases of COVID-19 infection. Cytokines such as interferon and hematopoietic growth factor have been used as therapy. Alternatively, the inhibition of cytokine functions has been largely developed using anti-interleukin or anti-TNF monoclonal antibodies in the treatment of sepsis or chronic inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482 · cited 1×
“It was reported in the CANTOS study that blockers of IL-1 may be beneficial against atherosclerosis, lung cancer and arthrosis [70].”
Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605
Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology
Funk, C. D. (2001) · Science · doi:10.1126/science.294.5548.1871 · Cited by 3,817 · cited 2×
“PGE2 is involved in the clinical inflammation signs: redness, pain and swelling [9].”
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · cited 1×
“The cytokine levels of IFNγ, IL-6 and IL-10 are found in chimeric antigen receptor T (CART)-cell-induced cytokine storm [63].”
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212 · cited 3×
“After gp130 dimerization, gp130‐associated Jak1 kinase is activated and leads to intracellular transmission, including jak/stat, ERk and P13k [36,37].”
Fajgenbaum, D. C., & June, C. H. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2026131 · Cited by 3,196
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806 · cited 1×
“C-reactive protein (CRP) and markers of inflammation are elevated and correlate with the severity [62].”
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
Dinarello, C. A. (2011) · Blood · doi:10.1182/blood-2010-07-273417 · Cited by 2,248 · cited 1×
“IL-1 receptor antagonist (IL-1Ra) binds to IL-R1 and prevents IL-1α and IL-1β activities [43].”
Opal, S. M., & DePalo, V. A. (2000) · Chest · doi:10.1378/chest.117.4.1162 · Cited by 1,752
Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity
Mantovani, A., Dinarello, C. A., Molgora, M., & Garlanda, C. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.012 · Cited by 1,046
Aggarwal, B. B., Gupta, S. C., & Kim, J. H. (2012) · Blood · doi:10.1182/blood-2011-04-325225 · Cited by 877 · cited 2×
“A more complete list was published in [46].”
Prostaglandin E2 synthesis and secretion: The role of PGE2 synthases
Park, J. Y., Pillinger, M. H., & Abramson, S. B. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.01.016 · Cited by 793 · cited 2×
“PGE synthase is colocalized with COX‐1 in the endoplasmic reticulum [14].”
Increased production of prostaglandin D2 in patients with systemic mastocytosis
Roberts, L. J., Sweetman, B. J., Lewis, R. A., Austen, K. F., & Oates, J. A. (1980) · New England Journal of Medicine · doi:10.1056/nejm198012113032405 · Cited by 423
Nemeth, E., & Ganz, T. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.04.005 · Cited by 401 · cited 1×
“The first target for the treatment of inflammatory anemia is to treat the underlaying disease; if anemia is severe, blood transfusion or treatment by erythropoietin-stimulating agents may be necessary [61].”
Spinal inflammatory hyperalgesia is mediated by prostaglandin E receptors of the EP2 subtype
Reinold, H., Ahmadi, S., Depner, U. B., Layh, B., Heindl, C., Hamza, M., Pahl, A., Brune, K., Narumiya, S., Müller, U., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23618 · Cited by 202 · cited 1×
“PGE2 has a contrasting effect in neuroinflammation [11,12].”
Kulesza, A., Paczek, L., & Burdzinska, A. (2023) · Biomedicines · doi:10.3390/biomedicines11020445 · Cited by 163
Metadata
- Authors
- Wautier, J.-L., & Wautier, M.-P.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-06-01
- Volume
- 24
- Issue
- 11
- Pages
- 9647
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4379233453
- Cited by
- 179
- References
- 16
- FWCI
- 22.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.